Drug Database
ET

etanercept

✓ Approved

Harvest Moon Pharmaceuticals · TNF · 重组蛋白

什么是 etanercept?

etanercept 是一种重组蛋白,由Harvest Moon Pharmaceuticals研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intraarticular Injection、Intravenous (IV)、Subcutaneous Injection。

药物档案

公司Harvest Moon Pharmaceuticals
药物类别重组蛋白
分子靶点TNF
给药途径Injectable (Others), Intraarticular Injection, Intravenous (IV), Subcutaneous Injection
状态Approved

作用机制

分子靶点

etanercept 作用于 1 个分子靶点:

TNFtumor necrosis factor (TNFA, TNF-alpha)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

etanercept 针对 5 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Musculoskeletal and connective tissue disordersRheumatoid arthritis✓ Approved
Musculoskeletal and connective tissue disordersAnkylosing spondylitisPreclinical
Skin and subcutaneous tissue disordersPsoriasisPreclinical
Musculoskeletal and connective tissue disordersPsoriatic arthropathyPreclinical
Musculoskeletal and connective tissue disordersJuvenile idiopathic arthritisPreclinical

相关研究文献

PubMedJournal of neuroinflammation2026-11-19

Necrotising enterocolitis triggers a TNF-driven gut-blood-brain cascade that disrupts the blood-brain barrier and induces TNFR1-skewed neuronal apoptosis and pyroptosis.

Wang Lin-Yu LY, Chen Tzu-Hao TH, Wang Liang-Chao LC, Chien Lan-Hsiang LH et al.

Necrotising enterocolitis (NEC) in very-low-birthweight (VLBW) infants is associated with neurodevelopmental difficulties, but the mechanisms linking intestinal disease to brain injury remain unclear. We asked whether NEC propagates along a tumour necrosis factor alpha (TNF-α)-centred gut-blood-brain pathway that compromises the blood-brain barrier (BBB) and activates inflammatory neuronal death programmes. In a retrospective cohort, inflammatory biomarkers at symptom onset (C-reactive protein and procalcitonin) were related to Bayley-III composite scores at 24 months' corrected age. We then used a neonatal rat NEC model with daily oral etanercept, a soluble TNF receptor fusion protein, or saline from postnatal day 2 to day 14 to assess intestinal histopathology and permeability, circulating microbial products, inflammation, BBB permeability, early neurobehaviour, microglial activation, and neuronal apoptosis and pyroptosis with TNF receptor (TNFR) localisation. An intestinal-epithelial cell-primary cortical neuron transwell co-culture tested whether LPS-injured epithelium was sufficient to release TNF-α, disrupt barrier integrity, and injure neurons, and whether etanercept mitigated these effects. In infants, higher C-reactive protein and procalcitonin at NEC onset were associated with lower Bayley-III motor, cognitive, and language scores. In rats, NEC caused small-intestinal injury with tight-junction loss and permeability, elevated circulating microbial products and TNF-α, increased BBB leak, activated microglia, and induced neuronal apoptosis and pyroptosis with a TNFR1-skewed and TNFR2-reduced profile. NEC also impaired early sensorimotor performance, and worse performance was associated with higher circulating C-reactive protein, procalcitonin, and TNF-α. Etanercept reduced inflammatory burden, improved intestinal and BBB integrity, and improved sensorimotor performance. In co-culture, LPS activated epithelial NF-κB and MAPK signalling, increased epithelial TNF-α, and reduced barrier resistance. Neurons exposed to this inflammatory milieu showed TNFR1 upregulation, TNFR2 downregulation, activation of apoptotic effectors, and NLRP1 inflammasome-linked pyroptotic signalling, accompanied by synaptic injury. Etanercept blunted upstream epithelial signalling, preserved barrier function, and reduced TNFR1-skewed neuronal injury programmes. Acute inflammatory burden at presentation tracked with poorer 24-month neurodevelopment, and experimental data support TNF signalling as a plausible, modifiable relay linking barrier failure to BBB dysfunction, microglial activation, and TNFR1-skewed neuronal injury. These findings support risk stratification using routine biomarkers and motivate mechanism-informed trials targeting inflammatory amplification in NEC.

PMID 43053046
阅读全文 →
PubMedJournal of big data2026-11-17

Context-specific drug scoring for precision repurposing via synergizing label propagation with heterogeneous networks.

Nam Yonghyun Y, Jung Sang-Hyuk SH, Woerner Jakob J, Lawrence Patrick J PJ et al.

While biological and pharmaceutical knowledge networks have significantly propelled drug repurposing efforts, reliance solely on these networks is insufficient for accurately addressing genetic and phenotypic variance. This limitation highlights the need for an integrative approach that leverages context-specific data to enhance the precision of drug repurposing. We introduce a network-based integrative drug scoring approach that synergistically incorporates data-driven and knowledge-driven networks without requiring their direct integration. We developed a synergistic label propagation algorithm that facilitates information transfer from data-driven to knowledge-driven networks. To enable context-specific drug repurposing, we constructed a data-driven disease-disease association network utilizing European-specific genetic information and a knowledge-driven drug-target protein association network. In a proof-of-concept study, drug scoring was applied to identify candidate drugs for rheumatoid arthritis, asthma, and multiple sclerosis. Compared with a representative direct-integration benchmark, the proposed method achieved an average AUC of 0.701, corresponding to a 9.71% improvement. These results provide preliminary evidence supporting the utility of the proposed framework. A supportive EHR-based medication association analysis using UK Biobank participants' medication records for rheumatoid arthritis highlighted three prioritized drugs or drug classes: Carfilzomib, Etanercept, and Artenimol. Overall, this framework provides a flexible strategy for incorporating context-specific genetic information into network-based drug repurposing.

PMID 43041454
阅读全文 →
PubMedReumatismo2026-11-11

Atypical adult polyarteritis nodosa unmasking deficiency of adenosine deaminase 2: a case report about the importance of genetic testing in adults.

Antolini Sofia S, Cassandrini Denise D, Bindoli Sara S, Bronte Vincenzo V et al.

Deficiency of adenosine deaminase 2 (DADA2) is an autosomal recessive autoinflammatory disorder caused by biallelic mutations in the ADA2 gene. It presents as a monogenic vasculitis with heterogeneous manifestations that often resemble small- and medium-vessel vasculitis, particularly polyarteritis nodosa (PAN)-like disease, leading to frequent misdiagnosis, especially in adults. Early recognition of DADA2 is crucial, as prompt treatment can control inflammation, preserve vascular integrity, and prevent irreversible organ damage.  Rising awareness of the wide clinical spectrum of DADA2 is fundamental to improve recognition and facilitate timely diagnosis, ultimately enhancing prognosis. We herein describe the case of a middle-aged woman with skin lesions, central nervous system, peripheral nervous system, and gastrointestinal tract ischemic manifestations who was initially diagnosed with PAN. The patient was treated with glucocorticoids as well as several steroid-sparing immunosuppressive agents (methotrexate, azathioprine, rituximab, tocilizumab, and cyclophosphamide), which all proved to be ineffective. Meanwhile, the patient developed cytopenias and hypogammaglobulinemia. Subsequent genetic testing identified a homozygous missense mutation in the ADA2 gene (c.1358A>G, p.Tyr453Cys), supporting the diagnosis of DADA2 and enabling the initiation of effective therapy with the tumor necrosis factor-α inhibitor etanercept. This case underscores the importance of considering DADA2 in adult patients presenting with recurrent vasculitic manifestations refractory to conventional immunosuppressive therapy, as timely genetic testing can be pivotal in redirecting treatment toward targeted and effective therapy.

PMID 43010799
阅读全文 →
PubMedPediatric rheumatology online journal2026-11-06

Infant-onset mevalonate kinase deficiency with a previously unreported MVK c.827 A > G (p.Glu276Gly) variant presenting as suspected incomplete kawasaki disease with marked hyperinflammation: clinical response to firsekibart and systematic evidence synthesis.

Shen Yang Y, Gao Yutong Y, Shan Jing J, He Xiaoliang X et al.

Mevalonate kinase deficiency (MKD) is an autosomal-recessive autoinflammatory disorder spanning a clinical continuum from the hyperimmunoglobulin-D syndrome/recurrent-fever phenotype to severe mevalonic aciduria. In infants, the first attacks can resemble infection, incomplete Kawasaki disease, or other forms of systemic hyperinflammation. Comparative evidence to guide treatment choice and dose adjustment remains limited. We describe a female infant with recurrent high fever and a generalized erythematous rash beginning at 1 month and 23 days of age. She was initially treated for suspected incomplete Kawasaki disease because fever, rash, leukocytosis, elevated C-reactive protein, and qualitatively reported mild coronary-artery dilatation were present; segment-specific coronary measurements and z scores were not available. Ferritin 1101.72 ng/mL, soluble CD25 34,200 pg/mL, reduced natural-killer-cell activity, cervical lymphadenopathy, and mild splenomegaly indicated marked hyperinflammation, but the available data were insufficient to diagnose hemophagocytic lymphohistiocytosis or macrophage activation syndrome. Trio whole-exome sequencing identified MVK c.439G > A (p.Ala147Thr), maternally inherited, and c.827 A > G (p.Glu276Gly), paternally inherited. The second variant was not listed in Infevers and was not identified in ClinVar or the peer-reviewed MKD literature searched on 13 July 2026. It was classified as likely pathogenic by the reporting laboratory, but laboratory-specific ACMG/AMP evidence codes and biochemical confirmation were unavailable. We also updated a systematic review of IL-1-targeted treatment in systemic MKD. Intravenous immunoglobulin and systemic corticosteroids produced transient improvement. An etanercept biosimilar provided only temporary control. Tocilizumab prolonged attack intervals but was discontinued after likely treatment-associated secondary hypogammaglobulinemia requiring intravenous immunoglobulin and subsequent relapse. Firsekibart (Jin Beixin; Changchun GeneScience Pharmaceutical Co., Ltd., Changchun, China), a fully human IgG4λ monoclonal antibody that selectively neutralizes IL-1β, was then given off-label at 40 mg subcutaneously (approximately 4 mg/kg) every 4 weeks; after the second dose, the interval was extended to 40 days. At the latest documented follow-up, five doses had been given and no typical fever-rash attacks or new treatment-related adverse events had been reported. The original database search identified 876 records and 7 eligible reports; a targeted update added 3 full-text studies, including the RELIANCE registry, for 10 reports in the final descriptive synthesis. Trial, extension, cohort, post-marketing, registry, and case-based evidence consistently supported IL-1 pathway inhibition. Dose escalation, interval modification, and individualized treat-to-target adjustment were frequent across the published reports. This case supports early MVK testing when recurrent infantile inflammation persists after treatment for suspected incomplete Kawasaki disease. The patient had marked hyperinflammation with several HLH-associated abnormalities, but not enough evidence for a formal HLH/MAS diagnosis. Her response is consistent with the established therapeutic rationale for IL-1 blockade in systemic MKD; however, the c.827 A > G variant requires fuller laboratory documentation, and the firsekibart observation remains a single-patient, short-term, agent-specific experience.

PMID 42989308
阅读全文 →
PubMedInflammation and regeneration2026-11-05

A human rheumatoid arthritis bone-cartilage interface organoid recapitulates bone, cartilage, and immune interactions.

Adams Mary M, Grieg Christopher C, Gonsiorek Waldemar W, Wetterstrand Charlene C et al.

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by synovial inflammation, cartilage degradation, and bone erosion. Fibroblast-like synoviocytes (FLS) play a central role in perpetuating joint damage, yet current therapies inadequately address FLS-driven pathology. Existing preclinical models, including murine collagen-induced arthritis and conventional in vitro cultures, lack the complexity to fully recapitulate human disease mechanisms. Here, we describe the development of a three-dimensional (3D) RA bone-cartilage interface (BCI) organoid that integrates primary human mesenchymal stem cell-derived osteoblasts, peripheral blood mononuclear cell-derived osteoclasts and lymphocytes, immortalized human chondrocyte spheroids, and the RA synovial fibroblast cell line SW982. Exposure to TNF-α, IL-1β, and TGF-β induced pro-inflammatory cytokines, matrix-degrading enzymes, and increased fibrotic gene expression, accompanied by histological and microCT evidence of bone dysregulation. Therapeutic testing showed that methotrexate, etanercept, and tofacitinib reduced cytokine production and pro-inflammatory gene expression but had limited impact on profibrotic gene expression. This modular, human-derived RA BCI organoid reproduced key features of RA pathogenesis that can enable direct assessment of therapeutic mechanisms at the bone-cartilage-synovial interface. The RA BCI organoid provides a physiologically relevant, scalable platform for preclinical drug discovery and for identifying combination strategies that address both the inflammatory and fibrotic components of RA pathology.

PMID 42983776
阅读全文 →
PubMedCureus2026-11-02

A Rare Case of Cystic Bronchiectasis With Concurrent Pulmonary Aspergillosis in a Rheumatoid Arthritis Patient Receiving Etanercept.

Samara Hanien H, Ghantarchyan Henrik H, Chandak Twinkle T

Tumor necrosis factor-alpha (TNF-α) is critical to the body's ability to mount an appropriate inflammatory and immune response to various infections, particularly against intracellular organisms. As such, the immunosuppressive effects associated with TNF-α inhibitors, such as etanercept, may increase susceptibility to opportunistic infections. We report a case of pulmonary Aspergillus infection in a 47-year-old female with rheumatoid arthritis receiving etanercept who was found to have underlying cystic bronchiectatic changes. The patient presented with progressive exertional dyspnea and was subsequently found to have right lower lobe cystic bronchiectatic changes with mass-like densities on computed tomography (CT) imaging. Sputum fungal culture was positive for Aspergillus, bronchoalveolar lavage (BAL) was positive for Aspergillus antigen, and fungal culture from a bronchoscopic biopsy specimen grew Aspergillus fumigatus. Other infectious evaluations were negative. The patient was treated with voriconazole, and etanercept was discontinued. This case highlights the diagnostic complexity of interpreting Aspergillus isolation in patients with underlying structural lung disease and TNF-α inhibitor exposure.

PMID 42968981
阅读全文 →

注册免费账户还可查看另外 8499 篇文献

免费注册查看全部文献 →

了解更多etanercept